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Abstract 
Aims 
High-grade (Perugini grade 2 or 3) cardiac uptake on bone scintigraphy with 99mTechnetium 
labelled 3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) has lately been 
confirmed to have high diagnostic sensitivity and specificity for cardiac transthyretin (ATTR) 
amyloidosis.  We sought to determine whether patient stratification by Perugini grade on 
99mTc-DPD scintigraphy has prognostic significance in ATTR amyloidosis.  
 
Methods and Results 
Patient survival from time of 99mTc-DPD scintigraphy was determined in 602 patients with 
ATTR amyloidosis, including 377 with wild-type ATTR and 225 with mutant ATTR 
amyloidosis (ATTRm).  Patients were stratified according to Perugini grade (0-3) on 99mTc-
DPD scan.  The prognostic significance of additional patient and disease-related factors at 
baseline were determined.  In the whole cohort, the finding of a Perugini grade 0 99mTc-DPD 
scan (n=28) was invariably associated with absence of cardiac amyloid according to 
consensus criteria as well as significantly better patient survival compared to a Perugini grade 
1 (n=28), 2 (n=436) or 3 (n=110) 99mTc-DPD scan (p<0.005).  There were no differences in 
survival between patients with a grade 1, grade 2 or grade 3 99mTc-DPD scan in wild-type 
ATTR (n=369), V122I-associated ATTRm (n=92) or T60A–associated ATTRm (n=59) 
amyloidosis.  Cardiac amyloid burden, determined by equilibrium contrast cardiac magnetic 
resonance imaging, was similar between patients with Perugini grade 2 and Perugini grade 3 
99mTc-DPD scans but skeletal muscle/soft tissue to femur ratio was substantially higher in the 
latter group (p<0.001).   
 
Conclusion 
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99mTc-DPD scintigraphy is exquisitely sensitive for identification of cardiac ATTR amyloid, 
but stratification by Perugini grade of positivity at diagnosis has no prognostic significance.   
 
Key Words – ATTR amyloidosis, prognosis, 99mTc-DPD, Perugini grade, skeletal muscle, 
soft tissue 
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Introduction 
Cardiac transthyretin (ATTR) amyloidosis is a rarely diagnosed infiltrative cardiomyopathy 
with an inexorably progressive clinical course and poor prognosis.  It is characterised by the 
relentless deposition and accumulation of fibrillar amyloid deposits in the extracellular space 
of the myocardium.  ATTR amyloid fibrils are composed of either wild-type or variant 
transthyretin, the latter associated with a multitude of mutations in the transthyretin (TTR) 
gene.1, 2  Wild-type ATTR amyloidosis is usually diagnosed in elderly males,3, 4 and mutant 
ATTR cardiac amyloidosis (ATTRm) is particularly prevalent in certain populations such as 
individuals of African descent and from North West Ireland in whom the respective 
pathogenic V122I and T60A TTR variants are present in 4%5 and 1%6 of individuals 
respectively.  Certain TTR variants, such as V30M, which is particularly prevalent in 
Swedish, Japanese and Portuguese populations, may result in a clinical phenotype of ATTR 
amyloidosis that is characterized by predominant autonomic and peripheral polyneuropathy 
in which the heart is spared.7  
The traditional gold standard for diagnosis of cardiac ATTR amyloidosis is 
demonstration of cardiac amyloid deposits in an endomyocardial biopsy in the context of a 
characteristic echocardiogram or cardiac magnetic resonance imaging (CMR) scan.  Recently 
however, cardiac uptake on bone scintigraphy with tracers such as 99mTechnetium 3,3-
diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) and pyrophosphate (99mTc-PYP) has 
been confirmed to have high diagnostic sensitivity and specificity for cardiac ATTR 
amyloidosis.8  Rapezzi and colleagues devised a simple four-stage grading system based on 
the intensity of uptake in the myocardium relative to that in the bones (Perugini grade 0-3).9   
The aim of our study was to determine whether patient stratification by Perugini grade 
on 99mTc-DPD scintigraphy has prognostic significance in ATTR amyloidosis, and to further 
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investigate the biological basis for the different 99mTc-DPD scan appearances across the 
Perugini grades. 
 
Methods 
Patients 
Six hundred and two patients with ATTR amyloidosis underwent 99mTc-DPD scintigraphy at 
the UK National Amyloidosis Centre between 2010 and 2016.  Wild-type ATTR amyloidosis 
and ATTRm amyloidosis were diagnosed in accordance with previously published criteria.8  
Patients were managed symptomatically, as previously described.3  Deaths were recorded by 
the UK Office for National Statistics (ONS) and death certificate data was obtained from the 
NHS Health and Social Care Information Centre (HSCIC).10  Censor date was 5th October 
2016. 
 All patients were managed in accordance with the Declaration of Helsinki and 
provided informed consent for publication of their data.  The study was approved by the 
Royal Free Hospital ethics committee. 
 
99mTc-DPD scintigraphy 
All patients were administered 700 MBq of 99mTc-DPD intravenously and imaged 3 hours 
later on either a General Electric (GE) Infinia Hawkeye 4 or GE Discovery 670 hybrid 
gamma camera.  Whole body images were acquired at a scan speed of 10 cm/min using low 
energy high resolution collimators and were immediately followed by a SPECT-CT (single 
photon emission computed tomography with a low-dose, non-contrast CT scan) of the heart, 
as previously described.11  The expected radiation dose from the entire procedure was 
6.7 mSv per patient.  
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Intensity of myocardial uptake on planar 99mTc-DPD scan was categorised as 0-3 
according to the widely used Perugini grading system.9  Briefly, this comprises: grade 0 – no 
cardiac uptake and normal bone uptake; grade 1 – cardiac uptake which is less intense than 
the bone signal; grade 2 – cardiac uptake with intensity similar or greater than bone signal; 
grade 3 – cardiac uptake with much attenuated or absent bone signal.   
Soft tissue to femur ratio was calculated in the whole cohort by placing a line profile 
region of interest across the mid thighs on the anterior whole body image and subsequently 
dividing the number of counts at the level of the skeletal muscle/soft tissue region by those at 
the adjacent femur level, as previously reported.11 
 
Echocardiography 
All patients underwent echocardiography at the UK National Amyloidosis Centre, as 
previously described.12  Presence or absence of cardiac ATTR amyloidosis was determined 
on the basis of consensus criteria, initially established for cardiac AL amyloidosis,13 with the 
addition in selected cases of gadolinium enhanced CMR imaging.14, 15  Briefly, presence of 
cardiac amyloidosis was defined by positive Congo red histology on endomyocardial biopsy 
and/or mean left ventricular wall thickness of >12 mm on echocardiography and/or presence 
of delayed gadolinium enhancement on CMR.   
 
Cardiac Magnetic Resonance Imaging 
A subset of 122 patients with cardiac ATTR amyloidosis from the cohort underwent 
equilibrium contrast CMR imaging within 24 hours of their 99mTc-DPD scan, on a 1.5-T 
clinical scanner (Avanto or Aera, Siemens Healthcare, Erlangen, Germany), reflecting the 
limited availability of this additional service.  Cardiac amyloid burden was estimated by 
calculation of extracellular volume (ECV), as previously described.15  Patients were stratified 
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according to Perugini grade on 99mTc-DPD scan and cardiac amyloid burden by CMR was 
compared between groups.   
 
Skeletal muscle histology 
Skeletal muscle biopsies were obtained in 6 of the patients from the cohort.  All muscle 
biopsies were stained with Congo red by the method of Puchtler et al.16  Amyloid deposits 
identified in these biopsies were typed immunohistochemically as previously described.17 
 
Statistical Analyses of Survival 
Patient survival from time of the baseline 99mTc-DPD scan was analysed by Kaplan Meier 
analysis using GraphPad Prism v5.03 software.  Patients were stratified according to Perugini 
grade on 99mTc-DPD scan and patient survival was compared using the log-rank test.  Patient 
and disease-related factors significantly associated with death by univariate analyses to a 0.1 
level, were investigated in the whole cohort by Cox proportional hazards regression analysis 
to establish those that were independently associated with death to a significance level of 0.05 
using IBM SPSS Statistics 23 software.  ECV and soft tissue to femur ratios were compared 
between groups by Mann-Whitney U test.   
 
Results 
Patients 
The cohort of 602 patients comprised 377 patients with wild-type ATTR amyloidosis, and 
225 patients with ATTRm amyloidosis.  Among patients with ATTRm amyloidosis, the most 
prevalent variants were V122I (n=92) and T60A (n=59), both of which are associated with a 
phenotype dominated by cardiac amyloidosis.  Cardiac ATTR amyloidosis, identified on the 
basis of echocardiography, histology and/or CMR was present in a total of 563/602 (94%) 
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patients.  Thirty-five patients had V30M–associated ATTR amyloidosis, which is 
predominantly a neuropathic disease, and in which cardiac involvement is often absent.  It is 
noteworthy that patients with V30M-associated ATTR amyloidosis had lower median LV 
wall thickness and NT-proBNP values in keeping with this clinical phenotype.  Patient 
demographics for the whole cohort and in each individual cohort at the time of the baseline 
99mTc-DPD scan are shown in Table 1.   
Median follow-up from baseline for the whole cohort was 29.6 months during which 
time 202 patients died.  Cause of death in almost all (>95%) patients was from ‘progressive 
amyloidosis’, usually associated with pneumonia or end-stage cardiac failure.   
 
99mTc-DPD scintigraphy in relation to survival 
Among 602 patients with ATTR amyloidosis, 28 had Perugini grade 0 99mTc-DPD scans, 28 
Perugini grade 1, 436 Perugini grade 2 and 110 had Perugini grade 3 99mTc-DPD scans.  
Ninety five percent of the whole cohort had abnormal cardiac uptake on 99mTc-DPD 
scintigraphy, the vast majority (91%) having a Perugini grade 2 or grade 3 99mTc-DPD scan.  
Survival was significantly longer (median not reached) in patients with a Perugini grade 0 
99mTc-DPD scan compared to those with a Perugini grade 1, Perugini grade 2 or Perugini 
grade 3 99mTc-DPD scan by Kaplan Meier analysis (log rank test, p=<0.04 for grade 0 vs each 
other grade).  There was no significant difference in survival between patients with Perugini 
grade 1, Perugini grade 2 or Perugini grade 3 scans (Figure 1, log rank test, p=0.39 for 
Perugini grade 1 vs Perugini grade 2; p=0.51 for Perugini grade 2 vs Perugini grade 3).  
Median estimated survival in those with a Perugini grade 1 99mTc-DPD scan was not reached, 
in those with a Perugini grade 2 99mTc-DPD scan was 55.3 months, and in those with a 
Perugini grade 3 99mTc-DPD scan was 46.5 months.   
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 Survival, stratified according to a Perugini grade 1, Perugini grade 2 and Perugini 
grade 3 99mTc-DPD scan, was separately compared in 3 different cohorts of patients; those 
with wild-type ATTR amyloidosis (n=377), those with V122I-associated ATTR amyloidosis 
(n=92), and those with T60A–associated ATTR amyloidosis (n=59).  There was no 
difference in survival on the basis of 99mTc-DPD scan grade of positivity in any of these 
patient cohorts (Figure 2A-C).  In 35 patients with V30M-associated ATTR amyloidosis, 
survival was significantly longer among the 19 patients without cardiac uptake of 99mTc-
DPD, none of whom had evidence of cardiac amyloidosis by consensus criteria, compared to 
16 patients with positive 99mTc-DPD scans (log rank test, p<0.02). 
 
Additional factors influencing survival 
The following additional factors were significant predictors of mortality in the whole cohort 
by univariable analyses; age (p<0.001), six minute walk test distance (p<0.001), left 
ventricular ejection fraction (p=0.002), Troponin T concentration (p<0.001), NT-proBNP 
concentration (p<0.001), ECOG performance status (p<0.001), supine systolic blood pressure 
(p<0.001), estimated glomerular filtration rate (eGFR) (p<0.001) and NYHA class (p<0.001). 
The only factors independently associated with mortality in a multivariable Cox 
proportional hazards model with age, ECOG performance status, left ventricular ejection 
fraction, 99mTc-DPD scan grade (0 vs 1/2/3), NT-proBNP concentration, supine systolic 
blood pressure (≤100 mmHg vs >100 mmHg), and eGFR as predictor variables were ECOG 
performance status (HR for 3 vs 0 of 9.5 [CI 1.9-47.4], p=0.006) and eGFR (HR 0.98 [CI 
0.96-0.99], p=0.002) (Table 2). 
 
Cardiac MRI versus 99mTc-DPD scintigraphy 
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An analysis of cardiac amyloid burden by CMR in a subset of 122 patients from the cohort 
showed a significant difference in cardiac amyloid burden between patients with a Perugini 
grade 0 99mTc-DPD scan compared to those with a Perugini grade 1 99mTc-DPD scan (Mann 
Whitney U test, p<0.004).  There was also a statistically significant difference in cardiac 
amyloid burden between those with Perugini grade 1 compared to Perugini grade 2 or 3 
99mTc-DPD scans, but with considerable overlap between the groups (Figure 3).  Comparison 
of cardiac amyloid burden between those with a Perugini grade 0 and those with a Perugini 
grade 2 or 3 99mTc-DPD scan showed no overlap between the groups and was highly 
significantly different (Mann Whitney U test, p=<0.0001). 
 
Soft tissue to femur ratio by 99mTc-DPD scintigraphy 
Soft tissue to femur ratio was significantly different between each Perugini grade of 99mTc-
DPD scan (p=0.002) with a particularly marked increase between Perugini grades 2 and 3 
(p<0.001) (Figure 4).  
 
Muscle biopsies 
ATTR amyloid was present in 3/3 skeletal muscle biopsies from patients with a Perugini 
grade 3 99mTc-DPD scan but in 0/1 with a Perugini grade 1 scan and 0/2 patients with a 
Perugini grade 2 99mTc-DPD scan.   
 
Discussion and Conclusions 
The findings presented in this large study of patients with ATTR amyloidosis, 91% of whom 
had a Perugini grade 2 or 3 99mTc-DPD scan at the time of diagnosis, indicate that there is no 
difference in prognosis between patients with different grades of abnormal cardiac uptake 
(i.e., Perugini grade 1, 2 or 3) by 99mTc-DPD scan, but that patients with no abnormal cardiac 
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uptake (Perugini grade 0) on 99mTc-DPD scan, indicating absence of cardiac ATTR cardiac 
amyloidosis, do fare better.  These data show that despite the previously reported high 
diagnostic sensitivity of abnormal cardiac uptake on 99mTc-DPD scintigraphy for cardiac 
ATTR amyloidosis and its utility in disease diagnosis,8 the specific grade of positivity 
according to the Perugini classification provides little prognostic information in ATTR 
amyloidosis.  Although our centre has no experience with 99mTc-PYP scintigraphy, which is 
widely used in North America for diagnosis of cardiac ATTR amyloidosis, our findings are in 
keeping with those reported by Castano et al,18 who performed a similar analysis in a cohort 
of patients injected with PYP tracer.  They also reported a non-significant Hazard ratio for 
grade 3 vs 2 (HR = 3.543 [95% CI of 0.474-26.455], p=0.22).  They did however, find that 
myocardial retention of 99mTc-PYP using the heart to contralateral ratio was independently 
associated with survival.  This raises the intriguing possibility that quantitative or semi 
quantitative measures may provide prognostic information not provided by the Perugini 
grading system.   
Ninety-seven percent (546/563) of patients in this cohort who were identified to have 
cardiac ATTR amyloidosis on the basis of a left ventricular wall thickness >12 mm by 
echocardiography and/or characteristic CMR findings and/or positive endomyocardial 
histology, presented with a Perugini grade 2 or Perugini grade 3 99mTc-DPD scan.  The 
difference between a Perugini grade 2 and a Perugini grade 3 99mTc-DPD scan is based on 
attenuation of the bone signal.  Whilst the latter has previously been attributed to competitive 
uptake of 99mTc-DPD in the heart versus the bones, we have previously demonstrated on 
planar whole body imaging that the apparent attenuation of bone signal reflects uptake of 
tracer in the skeletal muscle and/or soft tissue overlying the bones,11 further corroborated here 
by the highly significant increase in soft tissue to femur ratio observed in patients with a 
grade 3 99mTc-DPD scan compared to a Perugini grade 2 99mTc-DPD scan.   Amyloid in the 
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soft tissues and muscle has previously been reported as a clinical manifestation of ATTR 
amyloidosis,19 and muscle biopsies performed in a small subset of patients in this cohort 
confirmed skeletal muscle amyloid in all 3 patients with Perugini grade 3 99mTc-DPD scans, 
but none of 3 patients with Perugini grade 1 or 2 99mTc-DPD scans.  Whilst skeletal muscle 
amyloid deposits may be relatively scanty and of limited clinical significance, the total bulk 
of skeletal muscle in a patient may easily exceed 25 kg, compared to a typical myocardial 
mass of less than 0.5 kg.  Skeletal muscle amyloid may therefore represent a substantial 
compartment in terms of localisation of the 99mTc-DPD tracer, potentially competing with 
uptake into amyloid in the heart and thereby complicating its quantification by the Perugini 
grading method.  This is also the mechanism by which tracer uptake into the bones is 
obscured on visualisation of planar whole body imaging, resulting in the appearance of a 
Perugini grade 3 99mTc-DPD scan.   
Survival was superior among patients with Perugini grade 0 99mTc-DPD scans 
compared to those with Perugini grade 1, 2 or 3 99mTc-DPD scans.  Cardiac amyloid burden 
measured independently by equilibrium contrast cardiac magnetic resonance imaging was 
similar among patients with Perugini grade 2 or 3 99mTc-DPD scans, and was substantially 
greater than among patients with grade 0 99mTc-DPD scans with no overlap (p<0.0001).  
Although the cardiac amyloid burden by CMR in those with Perugini grade 1 99mTc-DPD 
scans was significantly less than in those with Perugini grade 2 or 3 99mTc-DPD scans, there 
was considerable overlap between these groups and no survival difference was detected.  
Given that <5% of patients in the cohort had Perugini grade 1 99mTc-DPD scans, the 
comparison between patients with grade 1 and patients with grades 2 or 3 99mTc-DPD scans 
should be interpreted with a degree of caution.  Nonetheless, these data serve to re-affirm the 
diagnostic sensitivity of 99mTc-DPD scintigraphy for cardiac ATTR amyloidosis, and 
corroborate previously reported findings which show that presence of cardiac involvement by 
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amyloid among patients with ATTR amyloidosis confers a poor prognosis.2, 20   It is 
noteworthy that a substantial proportion of patients (19/28) with Perugini grade 0 99mTc-DPD 
scans, none of whom had evidence of cardiac amyloid on either CMR or echocardiography, 
had V30M-associated ATTR amyloidosis and that their median age was 39 years.  It is well 
established that younger V30M-associated ATTR amyloidosis patients often have a 
phenotype characterised by polyneuropathy without cardiomyopathy.21  Multivariable 
analyses on the whole cohort showed that the only independent predictors of mortality were 
eGFR and ECOG performance status at baseline.   
In summary, 99mTc-DPD scintigraphy is exquisitely sensitive for identifying the 
presence of cardiac ATTR amyloid at the time of diagnosis.  Although a Perugini grade 2 or 3 
99mTc-DPD scan has a high diagnostic sensitivity and specificity for cardiac ATTR 
amyloidosis, it is the presence of cardiac amyloid indicated by abnormal cardiac uptake of 
99mTc-DPD into the heart rather than the Perugini grade of uptake that confers prognostic 
significance in patients with ATTR amyloidosis.  Uptake of tracer into skeletal muscle and 
soft tissue amyloid deposits is the chief cause of the attenuated bone signal among patients 
with grade 3 99mTc-DPD scans.  
 
Acknowledgements 
We thank our many physician colleagues for referring and caring for the patients.  Core 
support for the National Amyloidosis Centre is provided by NHS England, the UK National 
Institute for Health Research Biomedical Research Centre and Unit Funding Scheme.  DFH, 
MF and JDG were responsible for conceiving the study, interpreting the results and drafting 
the manuscript.  MB, AMQ, JCR, AP, JP, AMN, ADW, HJL, TR, CCQ, SM, SS, TY, CJW, 
TL, JAG, and DR were responsible for data collection and interpretation of results.  PNH 
14 
 
contributed to interpretation of results and critical review of the manuscript.  CCQ was 
granted a Research award from the Italian Ministry of Health – GR-2011-02352282. 
 
Conflict of interest 
None declare
15 
 
Table 1. Baseline characteristics 
Characteristic All patients 
N=602 
Wild-type ATTR 
N=377 
V122I ATTRm 
N=92 
T60A ATTRm 
N=59 
V30M ATTRm 
N=35 
Other ATTRm 
N=39 
Age  (median, range) (years) 75 (23 – 91) 77 (56 – 91) 76 (57 - 88) 69 (58 – 84) 50 (23 – 80) 55 (41 – 79) 
Male (%) 86 94 73 71 74 69 
NT-proBNP (median, range) (ng/L) 2765 (17 – 34910) 3188 (127 – 34910) 2791 (135 – 32272) 2250 (237 – 30657) 186 (17 – 2799) 1869 (17 – 15975) 
Troponin T (median, range) (ng/L) 63 (3 – 753) 62 (4 – 582) 87 (20 – 753) 55 (13 – 161) 12 (3 – 91) 42 (5 – 109) 
eGFR (median, range) (ml/min) 57 (10 – 100) 56 (18 – 100) 48 (10 - 100) 71 (10 – 100) 95 (45 – 100) 88 (28 – 100) 
Supine systolic BP (median, range) (mmHg) 121 (72 – 180) 122 (72 – 179) 120 (99 – 175) 114 (85 – 171) 124 (102 – 180) 119 (81 – 162) 
LV ejection fraction (median, range) (%) 49 (15 – 75) 48 (21 – 75) 43 (15 – 68) 50 (34 – 69) 60 (45 – 73) 55 (25 – 70) 
IVSd (median, range) (mm) 16 (8 – 25) 17 (9 – 25) 17 (12 – 22) 16 (12 – 23) 11 (9 – 20) 15 (8 – 23) 
6MWT distance (median, range) (metres) 345 (0 – 665) 346 (0 – 607) 272 (0 – 567) 394 (0 – 499) 368 (0 – 665) 385 (0 – 506) 
Cardiac amyloidosisǂ   Yes 
    No 
563 
39 
364 
13 
92 
0 
59 
0 
13 
22 
35 
4 
ECOG performance status          0 
            1 
                           2 
            3 
                                                   Missing 
54 
148 
114 
37 
249 
33 
99 
78 
18 
149 
5 
16 
17 
8 
46 
4 
22 
6 
6 
21 
6 
4 
4 
2 
19 
6 
7 
9 
3 
14 
NYHA functional class          1 
            2 
            3 
                                          4 
                                                   Missing 
95 
211 
93 
3 
200 
57 
130 
64 
1 
125 
7 
30 
16 
1 
38 
12 
26 
10 
1 
10 
13 
6 
0 
0 
16 
6 
19 
3 
0 
11 
DPD scintigraphy grade         Grade 0 
      Grade 1 
      Grade 2 
      Grade 3 
28 
28 
436 
110 
8 
14 
316 
39 
0 
0 
57 
35 
0 
0 
36 
23 
19 
4 
12 
0 
1 
10 
15 
13 
NT-proBNP, N-terminal pro-brain natriuretic peptide; eGFR, estimated glomerular filtration rate; BP, blood pressure; LV, left ventricular; IVSd, 
interventricular septal thickness at diastole; 6MWT, six minute walk test; ECOG, Eastern Cooperative Oncology Group; NYHA, New York 
Heart Association; DPD, 3,3-diphosphono-1,2-propanodicarboxylic acid.  ǂ - presence or absence of cardiac amyloidosis defined by 
echocardiography and/or CMR and/or endomyocardial histology. 
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Table 2.  Multivariable analysis of baseline factors influencing survival 
Factor Hazard Ratio P value Confidence Interval 
Perugini grade         0 
      1/2/3 
 
1 
0.68 
 
0.715 
 
0.089-5.235 
Age (per yr) 
 
1.00 0.854 0.973-1.034 
ECOG performance         0 
           1 
           2 
           3 
 
1 
2.06 
4.04 
9.53 
 
0.338 
0.066 
0.006 
 
0.469-9.048 
0.914-17.838 
1.914-47.432 
Supine systolic BP (mmHg)    >100 
                      ≤100 
 
1 
0.76 
 
0.617 
 
0.265-2.197 
eGFR (per ml) 
 
0.98 0.002 0.962-0.992 
LVEF (per percentage point) 
 
1.00 0.895 0.978-1.025 
NT-proBNP (per ng/L) 
 
1.00 0.695 0.999-1.000 
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Figure Legend 
Figure 1.  Survival of all patients with ATTR amyloidosis stratified by Perugini grade on 
99mTc-DPD scintigraphy.  Patients with no cardiac uptake on 99mTc-DPD scan (Perugini grade 
0) survived for significantly longer than those with abnormal cardiac uptake on 99mTc-DPD 
scan (log rank test, p<0.02 for grade 0 vs 1, p<0.002 for grade 0 vs 2 and p=0.0003 for 
grade 0 vs 3).  There was no significant difference in survival between patients with a 
Perugini grade 1, 2 or 3 99mTc-DPD scan (p=0.39 for grade 1 vs 2, p=0.19 for grade 1 vs 3, 
p=0.51 for grade 2 vs 3).   
 
Figure 2.  Survival in individual cohorts stratified by Perugini grade 1, 2 or 3 on 99mTc-DPD 
scintigraphy.  A) Survival in patients with wild-type ATTR amyloidosis stratified by Perugini 
grade 1, 2 or 3 99mTc-DPD scan (log rank test, p=0.89 for grade 1 vs 2, p=0.88 for grade 2 vs 
3).  B) Survival in patients with V122I-associated ATTR amyloidosis stratified by Perugini 
grade 2 or 3 99mTc-DPD scan (log rank test, p=0.49).  There were no patients with a Perugini 
grade 1 scan.  C) Survival in patients with T60A-associated ATTR amyloidosis stratified by 
Perugini grade 2 or 3 99mTc-DPD scan (log rank test, p=0.75).  There were no patients with a 
Perugini grade 1 scan.   
 
Figure 3.  Cardiac amyloid burden in relation to Perugini grade by 99mTc-DPD scintigraphy 
in a subset of 122 patients.  There is a significant difference in cardiac amyloid burden 
between patients with a Perugini grade 0 99mTc-DPD scan compared to those with a Perugini 
grade 1 99mTc-DPD scan (Mann Whitney U test, p<0.004).  There is also a statistically 
significant difference in cardiac amyloid burden between those with Perugini grade 1 
compared to Perugini grade 2 or 3 99mTc-DPD scans, but with considerable overlap between 
the groups.  Comparison of cardiac amyloid burden between those with a Perugini grade 0 
18 
 
and those with a Perugini grade 2 or 3 99mTc-DPD scan was highly significantly different 
with no overlap between the groups (Mann Whitney U test, p=<0.0001) 
 
Figure 4.  Soft tissue to femur ratio of counts in relation to Perugini grade by 99mTc-DPD 
scintigraphy.  There was a significant increase in soft tissue to femur ratio between all 
Perugini grades of 99mTc-DPD scan (p=0.002), with little overlap between those with a 
grade 2 and those with a grade 3 99mTc-DPD scan (p<0.001).  
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